BioCentury | May 25, 2018
Financial News

Consonance, Jay Mohr partner to invest in deprioritized therapeutics

...previously held executive positions at biotechs including cancer company Gloucester Pharmaceuticals Inc. and diagnostics company Variagenics Inc....
...which had its final close in 2014. Consonance Capital Partners, New York, N.Y. Mary Romeo Gloucester Pharmaceuticals Inc. Variagenics Inc....
BioCentury | May 22, 2018
Financial News

Consonance, Jay Mohr partner to invest in deprioritized therapeutics

...previously held executive positions at biotechs including cancer company Gloucester Pharmaceuticals Inc. and diagnostics company Variagenics Inc....
...on future runway for the fund, which had its final close in 2014. Mary Romeo Gloucester Pharmaceuticals Inc. Variagenics Inc. Consonance...
BioCentury | Jun 18, 2007
Tools & Techniques

Nuvelo's stealth target

...Ever since Nuvelo Inc. was formed through the merger of Hyseq Pharmaceuticals Inc. and Variagenics Inc. in...
BioCentury | Mar 27, 2006
Finance

Ebb & Flow

...first two financings following the creation of the company through the merger of Hyseq and Variagenics...
BioCentury | Sep 6, 2004
Strategy

Back to School 2004: Asset accumulation

...there were quite a few around then,” Love said. The choice was molecular diagnostics company Variagenics Inc....
...former name) 2002 Alfimeprase from Amgen Antibody generation and optimization technology from Genetastix $55.7M from Variagenics...
...former name) 2002 Alfimeprase from Amgen Antibody generation and optimization technology from Genetastix $55.7M from Variagenics...
BioCentury | Apr 19, 2004
Company News

Gloucester management update

...Business: Cancer Hired: Joseph Mohr as president, CEO and a director, formerly president and CBO Variagenics Inc. WIR...
BioCentury | Apr 13, 2004
Company News

Gloucester names Mohr CEO

...Joseph Mohr as president, CEO and a director. Mohr previously was president and CBO of Variagenics...
BioCentury | Mar 1, 2004
Strategy

Pharmacogenomics deals

...Perlegen and GSK to scan SNPs to identify genetic markers of drug response. NA 2002 Variagenics...
BioCentury | Jan 5, 2004
Company News

NaPro management update

...diagnostics and reagents and general manager of NPRO's genomics division, formerly VP of diagnostics at Variagenics Inc. WIR...
BioCentury | Oct 2, 2003
Financial News

Nuvelo raises $24.5 million

...compound is partnered with Amgen (AMGN). NUVO was formed by the merger of Hyseq and Variagenics...
Items per page:
1 - 10 of 112
BioCentury | May 25, 2018
Financial News

Consonance, Jay Mohr partner to invest in deprioritized therapeutics

...previously held executive positions at biotechs including cancer company Gloucester Pharmaceuticals Inc. and diagnostics company Variagenics Inc....
...which had its final close in 2014. Consonance Capital Partners, New York, N.Y. Mary Romeo Gloucester Pharmaceuticals Inc. Variagenics Inc....
BioCentury | May 22, 2018
Financial News

Consonance, Jay Mohr partner to invest in deprioritized therapeutics

...previously held executive positions at biotechs including cancer company Gloucester Pharmaceuticals Inc. and diagnostics company Variagenics Inc....
...on future runway for the fund, which had its final close in 2014. Mary Romeo Gloucester Pharmaceuticals Inc. Variagenics Inc. Consonance...
BioCentury | Jun 18, 2007
Tools & Techniques

Nuvelo's stealth target

...Ever since Nuvelo Inc. was formed through the merger of Hyseq Pharmaceuticals Inc. and Variagenics Inc. in...
BioCentury | Mar 27, 2006
Finance

Ebb & Flow

...first two financings following the creation of the company through the merger of Hyseq and Variagenics...
BioCentury | Sep 6, 2004
Strategy

Back to School 2004: Asset accumulation

...there were quite a few around then,” Love said. The choice was molecular diagnostics company Variagenics Inc....
...former name) 2002 Alfimeprase from Amgen Antibody generation and optimization technology from Genetastix $55.7M from Variagenics...
...former name) 2002 Alfimeprase from Amgen Antibody generation and optimization technology from Genetastix $55.7M from Variagenics...
BioCentury | Apr 19, 2004
Company News

Gloucester management update

...Business: Cancer Hired: Joseph Mohr as president, CEO and a director, formerly president and CBO Variagenics Inc. WIR...
BioCentury | Apr 13, 2004
Company News

Gloucester names Mohr CEO

...Joseph Mohr as president, CEO and a director. Mohr previously was president and CBO of Variagenics...
BioCentury | Mar 1, 2004
Strategy

Pharmacogenomics deals

...Perlegen and GSK to scan SNPs to identify genetic markers of drug response. NA 2002 Variagenics...
BioCentury | Jan 5, 2004
Company News

NaPro management update

...diagnostics and reagents and general manager of NPRO's genomics division, formerly VP of diagnostics at Variagenics Inc. WIR...
BioCentury | Oct 2, 2003
Financial News

Nuvelo raises $24.5 million

...compound is partnered with Amgen (AMGN). NUVO was formed by the merger of Hyseq and Variagenics...
Items per page:
1 - 10 of 112